Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Outcome After Lumbar Epidural Steroid Injection

This study has been completed.
Cytonics Corporation
Information provided by:
Scuderi, Gaetano J., M.D. Identifier:
First received: March 1, 2010
Last updated: NA
Last verified: March 2010
History: No changes posted
prospectively validate a fibronectin-aggrecan complex as a biomarker for response to ESI for radiculopathy with HNP

Disc Disease

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Functional Outcome After Lumbar Epidural Steroid Injection

Further study details as provided by Scuderi, Gaetano J., M.D.:

Primary Outcome Measures:
  • functional outcome on SF-36 following ESI [ Time Frame: 2-6 weeks ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA
lavage fluid from epidural space

Enrollment: 26
Study Start Date: March 2008
Study Completion Date: March 2010
Primary Completion Date: March 2010 (Final data collection date for primary outcome measure)
Detailed Description:
We will measure levels of the protein complex in the epidural space of patients undergoing lumbar ESI for radiculopathy with HNP. We assess functional outcomes at baseline and after treatment with the Medical Outcomes Study Short Form-36 instrument (SF-36). Our hypothesis was that the complex is present in patients with clinically significant functional improvement after ESI.

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients considered candidates for ESI were 18 years of age or greater with a history of leg sensory complaints primarily dictated by pain with associated sensory symptoms and/or low back pain for two weeks or more who had failed expectant management with NSAIDS, activity modification, and/or physical therapy.

Inclusion Criteria:

  • Acute onset of sensory symptoms with the primary complaint as pain as well as varying sensory symptoms (e.g. tingling, numbness) in one or more lumbar nerve root distributions
  • Positive physical exam findings including sensory findings consistent with a spinal nerve root, a positive straight leg raise test, and/or a diminished patellar or Achilles DTR consistent with sensory symptoms; AND
  • MRI of lumbar spine positive for HNP in a distribution correlating with physical examination

Exclusion Criteria:

  • Plain radiography demonstrating severe loss of disc height, high grade DDD, spondylolisthesis greater than grade I
  • A history of prior lumbar surgery or trauma, weakness in a consistent distribution (non-progressive with strength at least 4/5)
  • Red flags including progressive weakness, bowel/bladder complaints, radiographic unknown mass, unexpected weight loss; AND
  • Diagnosis of inflammatory arthritides, crystalline arthropathies, or other rheumatologic diseases
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01079026

Sponsors and Collaborators
Scuderi, Gaetano J., M.D.
Cytonics Corporation
Principal Investigator: Gaetano J Scuderi, MD Stanford University
  More Information

Responsible Party: Gaetano J Scuderi, MD, Stanford University Identifier: NCT01079026     History of Changes
Other Study ID Numbers: CYt.003 
Study First Received: March 1, 2010
Last Updated: March 1, 2010
Health Authority: United States: Institutional Review Board

Keywords provided by Scuderi, Gaetano J., M.D.:
epidural steroid
hnp processed this record on October 25, 2016